EFFECT OF PRETRANSPLANT ERYTHROPOIETIN THERAPY ON RENAL ALLOGRAFT OUTCOME
| Autor: | Raymond Pollak, Eva M. Vasquez |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty medicine.medical_treatment Urology Disease Adjuvants Immunologic hemic and lymphatic diseases medicine Humans Erythropoietin Transplantation Chemotherapy Kidney business.industry Incidence (epidemiology) Graft Survival Middle Aged Kidney Transplantation Surgery Clinical trial Treatment Outcome surgical procedures operative medicine.anatomical_structure Acute Disease Population study Female business medicine.drug |
| Zdroj: | Transplantation. 62:1026-1028 |
| ISSN: | 0041-1337 |
| DOI: | 10.1097/00007890-199610150-00024 |
| Popis: | Erythropoietin (EPO) is widely used among patients with end-stage renal disease awaiting transplantation. Data suggest that EPO therapy may be immunomodulatory. The purpose of this study was to assess the effects of pretransplant EPO therapy on renal allograft outcome. We evaluated 120 consecutive renal transplant recipients to assess the effect of EPO on graft outcome following renal transplantation. Among the study population, 58 patients were receiving EPO before transplantation (EPO group) and 62 patients were not treated with EPO (non-EPO group). Twenty-four of 58 EPO-treated patients (41%) experienced delayed graft function after transplantation, compared with 11 of 62 (18%) non-EPO-treated patients (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|